GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (TSX:WLLW) » Definitions » Debt-to-Asset

Willow Biosciences (TSX:WLLW) Debt-to-Asset : 0.79 (As of Dec. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Willow Biosciences Debt-to-Asset?

Willow Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$0.97 Mil. Willow Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$1.00 Mil. Willow Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was C$2.49 Mil. Willow Biosciences's debt to asset for the quarter that ended in Dec. 2024 was 0.79.


Willow Biosciences Debt-to-Asset Historical Data

The historical data trend for Willow Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences Debt-to-Asset Chart

Willow Biosciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.02 0.04 0.32 0.79

Willow Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.44 0.53 0.56 0.79

Competitive Comparison of Willow Biosciences's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's Debt-to-Asset falls into.


;
;

Willow Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Willow Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Willow Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences  (TSX:WLLW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Willow Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. It has a geographic presence in Canada and the United states, in which it generates the majority of its revenue from the United states.
Executives
Christopher Kenneth Savile Director, Senior Officer
Travis Doupe Senior Officer
Patricia Ranija Choudhary Director
Sadiq Lalani Director
Barbara Elaine Munroe Director
Peter Seufer-wasserthal Director
Trevor Anthony Peters Director, Senior Officer
Troy Tapan Talkkari Senior Officer

Willow Biosciences Headlines

No Headlines